These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 28521068)

  • 21. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
    Ma G; Zhang R; Wu X; Wang D; Ying K
    Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Generic versus branded enoxaparin in prophylaxis and treatment of vein thrombosis.
    Casella IB; Puech-Leão P
    Rev Assoc Med Bras (1992); 2015; 61(1):44-50. PubMed ID: 25909208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The safety and efficacy of use of low-molecular-weight heparin in pediatric neurosurgical patients.
    Gonda DD; Fridley J; Ryan SL; Briceño V; Lam SK; Luerssen TG; Jea A
    J Neurosurg Pediatr; 2015 Sep; 16(3):329-34. PubMed ID: 26067336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Retrospective comparison of two enoxaparin dosing and monitoring protocols at a pediatric hospital.
    Wolsey A; Wilcox RA; Olson JA; Boehme S; Anderson CR
    Am J Health Syst Pharm; 2019 May; 76(11):815-819. PubMed ID: 31361813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IV Versus Subcutaneous Enoxaparin in Critically Ill Infants and Children: Comparison of Dosing, Anticoagulation Quality, Efficacy, and Safety Outcomes.
    Diab YA; Ramakrishnan K; Ferrell B; Chounoune R; Alfares FA; Endicott KM; Rooney S; Corcoran J; Zurakowski D; Berger JT; Shankar V; Nath DS
    Pediatr Crit Care Med; 2017 May; 18(5):e207-e214. PubMed ID: 28296662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes of Prophylactic Enoxaparin Against Venous Thromboembolism in Hospitalized Children.
    Bennett E; Delgado-Corcoran C; Pannucci CJ; Wilcox R; Heyrend C; Faustino EV
    Hosp Pediatr; 2022 Jun; 12(6):617-625. PubMed ID: 35531629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective cohort study comparing achieved anti-factor Xa peak levels in pregnant and non-pregnant patients receiving therapeutic-dose low-molecular-weight heparin.
    Aleidan FAS; Aljarba GA; Aldakhil AA; Allehyani BI; Yahia MA; Alghtani NE; Badri M; Alaklabi AA; Alsuhaibani A; Crowther MA
    Int J Hematol; 2020 Jul; 112(1):1-7. PubMed ID: 32266670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Establishment of prophylactic enoxaparin dosing recommendations to achieve targeted anti-factor Xa concentrations in children with CHD.
    Israel EN; Thomas CA; Mastropietro CW
    Cardiol Young; 2018 May; 28(5):715-718. PubMed ID: 29490713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monitoring anti-Xa levels in patients with cancer-associated venous thromboembolism treated with bemiparin.
    Galeano-Valle F; Pérez-Rus G; Demelo-Rodríguez P; Ordieres-Ortega L; Ortega-Morán L; Muñoz-Martín AJ; Medina-Molina S; Alvarez-Sala-Walther LA; Del-Toro-Cervera J
    Clin Transl Oncol; 2020 Aug; 22(8):1312-1320. PubMed ID: 31863355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peak plasma anti-Xa levels after first and third doses of enoxaparin in women receiving weight-based thromboprophylaxis following caesarean section: a prospective cohort study.
    Hiscock RJ; Casey E; Simmons SW; Walker SP; Newell PA
    Int J Obstet Anesth; 2013 Nov; 22(4):280-8. PubMed ID: 23958275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enoxaparin use in the neonatal intensive care unit: experience over 8 years.
    Malowany JI; Knoppert DC; Chan AK; Pepelassis D; Lee DS
    Pharmacotherapy; 2007 Sep; 27(9):1263-71. PubMed ID: 17723080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients.
    Ludwig KP; Simons HJ; Mone M; Barton RG; Kimball EJ
    Ann Pharmacother; 2011 Nov; 45(11):1356-62. PubMed ID: 22009998
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-Xa levels in bariatric surgery patients receiving prophylactic enoxaparin.
    Rowan BO; Kuhl DA; Lee MD; Tichansky DS; Madan AK
    Obes Surg; 2008 Feb; 18(2):162-6. PubMed ID: 18165884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
    Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
    Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Capillary blood samples for anti-Xa monitoring of heparin in paediatric patients.
    Ridsdale S; Martin V; Payne JH
    Thromb Haemost; 2017 Jan; 117(1):198-200. PubMed ID: 27761575
    [No Abstract]   [Full Text] [Related]  

  • 36. Description of anti-Xa monitoring practices during low molecular weight heparin use.
    Lin A; Vazquez SR; Jones AE; Witt DM
    J Thromb Thrombolysis; 2019 Nov; 48(4):623-628. PubMed ID: 31317300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. If some is good, more is better: An enoxaparin dosing strategy to improve pharmacologic venous thromboembolism prophylaxis.
    Berndtson AE; Costantini TW; Lane J; Box K; Coimbra R
    J Trauma Acute Care Surg; 2016 Dec; 81(6):1095-1100. PubMed ID: 27244575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of enoxaparin dosing requirements in infants and children. Better dosing to achieve therapeutic levels.
    Bauman ME; Belletrutti MJ; Bajzar L; Black KL; Kuhle S; Bauman ML; Patricia Massicotte M
    Thromb Haemost; 2009 Jan; 101(1):86-92. PubMed ID: 19132193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin.
    Gibson JL; Ekevall K; Walker I; Greer IA
    Br J Obstet Gynaecol; 1998 Jul; 105(7):795-7. PubMed ID: 9692422
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population Pharmacokinetics of Enoxaparin in Pediatric Patients.
    Moffett BS; Lee-Kim Y; Galati M; Mahoney D; Shah MD; Teruya J; Yee D
    Ann Pharmacother; 2018 Feb; 52(2):140-146. PubMed ID: 28962537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.